Sanofi CEO uses Lemtrada's step forward to tout R&D future

Sanofi CEO Chris Viehbacher

Sanofi ($SNY) CEO Chris Viehbacher paid tribute to his Genzyme unit's MS drug candidate Lemtrada as the FDA accepted the company's application for its U.S. approval. Viehbacher also pointed to Sanofi's retooled R&D operation--and outlined plans for bolt-on deals, provided he can find some decently priced assets. Report

 

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.